Search research articles
Contact Us
Filters
Showing results (111-120 of 175) with videos related to
Page
of 18
Sort By:
Clinical Chemistry and Laboratory Medicine
|
March 11, 2025
A survey on measurement and reporting of total testosterone, sex hormone-binding globulin and free testosterone in clinical laboratories in Europe
Nick Narinx, Jennifer Afrakoma Nyamaah, Karel David, et al.
Scientific Reports
|
September 26, 2019
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
Florian Handle, Stefan Prekovic, Christine Helsen, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
September 25, 2015
Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
Evelien Gielen, Terence W O'Neill, Stephen R Pye, et al.
Expert Review of Anticancer Therapy
|
November 23, 2020
Current and emerging therapies for localized high-risk prostate cancer
Lisa Moris, Gaëtan Devos, Thomas Van den Broeck, et al.
Disease Models & Mechanisms
|
April 27, 2023
Crosstalk between androgen receptor and WNT/β-catenin signaling causes sex-specific adrenocortical hyperplasia in mice
Rodanthi Lyraki, Anaëlle Grabek, Amélie Tison, et al.
Molecular Cancer Therapeutics
|
September 27, 2018
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Florian Handle, Martin Puhr, Georg Schaefer, et al.
Endocrinology
|
December 13, 2021
Concordant Androgen-Regulated Expression of Divergent Rhox5 Promoters in Sertoli Cells
Anjana Bhardwaj, Abhishek Sohni, Chih-Hong Lou, et al.
Scientific Reports
|
February 4, 2016
Multidisciplinary investigation links backward-speech trait and working memory through genetic mutation
Stefan Prekovic, Dušica Filipović Đurđević, Gábor Csifcsák, et al.
Nature Communications
|
February 7, 2017
Structure of the homodimeric androgen receptor ligand-binding domain
Marta Nadal, Stefan Prekovic, Nerea Gallastegui, et al.
BMC Cancer
|
April 3, 2018
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
Lorenzo Tosco, Annouschka Laenen, Thomas Gevaert, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 175) with videos related to
Sort By:
Page
of 18
Clinical Chemistry and Laboratory Medicine
|
March 11, 2025
A survey on measurement and reporting of total testosterone, sex hormone-binding globulin and free testosterone in clinical laboratories in Europe
Nick Narinx, Jennifer Afrakoma Nyamaah, Karel David, et al.
Scientific Reports
|
September 26, 2019
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
Florian Handle, Stefan Prekovic, Christine Helsen, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
September 25, 2015
Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
Evelien Gielen, Terence W O'Neill, Stephen R Pye, et al.
Expert Review of Anticancer Therapy
|
November 23, 2020
Current and emerging therapies for localized high-risk prostate cancer
Lisa Moris, Gaëtan Devos, Thomas Van den Broeck, et al.
Disease Models & Mechanisms
|
April 27, 2023
Crosstalk between androgen receptor and WNT/β-catenin signaling causes sex-specific adrenocortical hyperplasia in mice
Rodanthi Lyraki, Anaëlle Grabek, Amélie Tison, et al.
Molecular Cancer Therapeutics
|
September 27, 2018
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Florian Handle, Martin Puhr, Georg Schaefer, et al.
Endocrinology
|
December 13, 2021
Concordant Androgen-Regulated Expression of Divergent Rhox5 Promoters in Sertoli Cells
Anjana Bhardwaj, Abhishek Sohni, Chih-Hong Lou, et al.
Scientific Reports
|
February 4, 2016
Multidisciplinary investigation links backward-speech trait and working memory through genetic mutation
Stefan Prekovic, Dušica Filipović Đurđević, Gábor Csifcsák, et al.
Nature Communications
|
February 7, 2017
Structure of the homodimeric androgen receptor ligand-binding domain
Marta Nadal, Stefan Prekovic, Nerea Gallastegui, et al.
BMC Cancer
|
April 3, 2018
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
Lorenzo Tosco, Annouschka Laenen, Thomas Gevaert, et al.
Page
of 18